calcimycin and 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic-acid

Human peritoneal eosinophils were obtained from the waste dialysis bags of patients undergoing continuous ambulatory peritoneal dialysis. The number of eosinophils obtained from each bag varied from 3 X 10(7) to 288 X 10(7). The cells were incubated for 1 h in tissue culture medium and prostaglandin E2 (PGE2), 6-keto-prostaglandin F1 (6-keto-PGF1), and thromboxane B2 (TXB2) were determined by radioimmunoassay of the supernatant. The basal release as well as the stimulated release from the purified eosinophils of TXB2 were five times greater than the release of PGE2 and thirty times greater than the release of 6-keto-PGF1. A dose-response curve was achieved for all three cyclooxygenase products with the calcium ionophore A23187. The release of TXB2 was inhibited in a dose-dependent manner by the specific thromboxane A2 (TXA2) synthase inhibitor OKY-1581 and a corresponding increase in PGE2 and 6-keto-PGF1 was obtained. Indomethacin (5.6 X 10(-6) M) inhibited the cyclooxygenase products to almost undetectable levels.

Topics: 6-Ketoprostaglandin F1 alpha; Arachidonic Acid; Arachidonic Acids; Calcimycin; Dinoprostone; Eosinophils; Epoprostenol; Humans; Indomethacin; Methacrylates; Peritoneal Cavity; Peritoneal Dialysis, Continuous Ambulatory; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Thromboxane A2

Topics: 6-Ketoprostaglandin F1 alpha; Calcimycin; Humans; Kidney Failure, Chronic; Macrophages; Methacrylates; Peritoneal Dialysis, Continuous Ambulatory; Thromboxane B2; Thromboxane-A Synthase; Thromboxanes